Related Experiment Video
Updated: May 7, 2026

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
Megalin contributes to kidney accumulation and nephrotoxicity of colistin
Takahiro Suzuki1, Hiroaki Yamaguchi, Jiro Ogura
1Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Abstract:
Interest has recently been shown again in colistin because of the increased prevalence of infections caused by multidrug-resistant Gram-negative bacteria. Although the potential for nephrotoxicity is a major dose-limiting factor in colistin use, little is known about the mechanisms that underlie colistin-induced nephrotoxicity. In this study, we focused on an endocytosis receptor, megalin, that is expressed in renal proximal tubules, with the aim of clarifying the role of megalin in the kidney accumulation and nephrotoxicity of colistin. We examined the binding of colistin to megalin by using a vesicle assay. The kidney accumulation, urinary excretion, and concentrations in plasma of colistin in megalin-shedding rats were also evaluated. Furthermore, we examined the effect of megalin ligands and a microtubule-depolymerizing agent on colistin-induced nephrotoxicity. We found that cytochrome c, a typical megalin ligand, inhibited the binding of colistin to megalin competitively. In megalin-shedding rats, renal proximal tubule colistin accumulation was decreased (13.5 ± 1.6 and 21.3 ± 2.6 μg in megalin-shedding and control rats, respectively). Coadministration of colistin and cytochrome c or albumin fragments resulted in a significant decrease in urinary N-acetyl-β-d-glucosaminidase (NAG) excretion, a marker of renal tubular damage (717.1 ± 183.9 mU/day for colistin alone, 500.8 ± 102.4 mU/day for cytochrome c with colistin, and 406.7 ± 156.7 mU/day for albumin fragments with colistin). Moreover, coadministration of colistin and colchicine, a microtubule-depolymerizing agent, resulted in a significant decrease in urinary NAG excretion. In conclusion, our results indicate that colistin acts as a megalin ligand and that megalin plays a key role in the accumulation in the kidney and nephrotoxicity of colistin. Megalin ligands may be new targets for the prevention of colistin-induced nephrotoxicity.
Insights
Colistin
Area of Science:
- Nephrology
- Pharmacology
- Molecular Biology
Background:
- Colistin is crucial for treating multidrug-resistant Gram-negative bacterial infections.
- Nephrotoxicity limits colistin dosage, but its mechanisms remain unclear.
- Megalin, an endocytosis receptor in renal proximal tubules, is investigated for its role in colistin's kidney effects.
Purpose of the Study:
- To elucidate the role of megalin in colistin-induced kidney accumulation and toxicity.
- To investigate colistin's interaction with megalin.
- To explore potential strategies for preventing colistin nephrotoxicity.
Main Methods:
- Vesicle assay to examine colistin-megalin binding.
- Evaluation of colistin levels in kidney, urine, and plasma of megalin-shedding rats.
- Assessment of colistin nephrotoxicity with megalin ligands and colchicine.
Main Results:
- Cytochrome c competitively inhibited colistin binding to megalin.
- Colistin accumulation in renal proximal tubules was reduced in megalin-shedding rats.
- Coadministration of colistin with megalin ligands (cytochrome c, albumin fragments) or colchicine significantly reduced urinary N-acetyl-β-d-glucosaminidase (NAG) excretion, a marker of kidney damage.
Conclusions:
- Colistin functions as a megalin ligand.
- Megalin is critical for colistin's accumulation in the kidneys and subsequent nephrotoxicity.
- Megalin ligands present a potential therapeutic target for mitigating colistin-induced kidney damage.
More Related Videos
06:19Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections
Published on: October 11, 2024
07:20Colonization with Murine pks+ Escherichia coli under Non-Inflammatory Conditions
Published on: March 10, 2026
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Inhibitors of Bacterial Protein Synthesis
Drugs that Destabilize Microtubules
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Clinical Significance of Antibiotic Resistance
Drug Elimination by Renal Route: Tubular Secretion